Oscotec Inc.
039200.KQ - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.37T
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.37 Trillion |
|---|---|
| Enterprise Value | $1.36 Trillion |
| Earnings per Share | $1368.38 |
| Beta | 0.3 |
| Outstanding Shares | 38,258,176 |
Return
| Return on Equity | 43.66% |
|---|---|
| Return on Assets | 35.28% |
| Return on Invested Capital | 39.98% |
Valuation & Multiples
| P/E Ratio | 14.53 |
|---|---|
| PEG | -0.7 |
| Price to Sales | 9.5 |
| Price to Book Ratio | 6.11 |
| Enterprise Value to Revenue | 9.43 |
| Enterprise Value to EBIT | 14.88 |
| Enterprise Value to Net Income | 14 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 14, 2026
EPS
$958.14
Est. -$324.20Revenue
$52.65 B
Est. $1.06 BNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
-$324.20
Consensus analyst estimateRevenue Estimate
$1.06 B
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Oscotec Inc.
50 employees
CEO: Tae-Young Yun
Oscotec Inc. is a biopharmaceutical company specializing in the discovery and development of novel therapeutic drugs. Its primary focus lies in advancing a pipeline of investigational medicines, including a SYK inhibitor currently in Pha...